Form 4: Alto Neuroscience CMO Granted 124,000 Stock Options

Alto Neuroscience's Chief Medical Officer, Adam Savitz, was granted 124,000 employee stock options with an exercise price of $16.71.

Summary

• Adam Savitz, Chief Medical Officer of Alto Neuroscience, Inc. (ANRO), was granted 124,000 employee stock options.
• The options have an exercise price of $16.71 per share.
• The grant date for these options was February 11, 2026.
• The options will vest over time, with 25% vesting on February 11, 2027, and the remainder vesting monthly thereafter over 36 months (1/48th per month), subject to continuous service.
• The expiration date for these options is February 10, 2036.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it signifies the company's commitment to retaining and incentivizing its Chief Medical Officer, a critical role in a neuroscience company. While not directly impacting immediate financials, it supports long-term stability and alignment.

Positives

• The grant of 124,000 stock options to the Chief Medical Officer aligns his incentives with long-term shareholder value creation.
• The vesting schedule encourages continuous service and retention of a key executive.

Risks

• The value of the options is contingent on the company's stock price exceeding the exercise price of $16.71, meaning there is no guaranteed value for the recipient if the stock underperforms.
• The vesting schedule is subject to the reporting person's continuous service, meaning unvested options could be forfeited if employment ceases.

Future Outlook

The options have a vesting schedule extending to February 11, 2027, for the initial 25% and then monthly thereafter, indicating a long-term incentive structure for the Chief Medical Officer. The expiration date of February 10, 2036, provides a long window for potential exercise.

Industry Context

Stock option grants are a standard component of executive compensation packages in the biotechnology and pharmaceutical industries, particularly for growth-oriented companies like Alto Neuroscience. StockSavvy.ai notes that such grants are designed to attract, retain, and motivate key talent by aligning their financial interests with the company's long-term performance and shareholder value creation.

Comparison to Industry Standards

• The grant of 124,000 stock options to a Chief Medical Officer is within the typical range for executive compensation in early to mid-stage biotechnology companies, comparable to grants seen at peers like Neurocrine Biosciences or Sage Therapeutics for similar roles, depending on company size and stage.
• The 10-year expiration period is also standard for employee stock options.

Stakeholder Impact

• Shareholders: Potential long-term alignment of executive interests with shareholder value; potential future dilution if options are exercised.
• Employees: Reflects standard executive compensation practices, potentially boosting morale by demonstrating commitment to key personnel.

Next Steps

• The Chief Medical Officer will continue to provide service to the company to meet the vesting conditions for the options.
• The company's stock performance will determine the ultimate value of these options for the recipient.

Key Dates

Recommendation

This Form 4 filing reports a routine executive compensation event (stock option grant) and does not contain information that would fundamentally alter the investment thesis for Alto Neuroscience. It reinforces management's long-term incentive structure but provides no new operational or financial data to warrant a change in investment recommendation. Investors should continue to hold based on the company's underlying fundamentals and pipeline progress.

Keywords

Alto Neuroscience, ANRO, stock options, employee compensation, insider transaction, Form 4, Chief Medical Officer, Adam Savitz, equity grant, vesting